Recent News

• 08.20.2025 - Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
• 05.18.2025 - Molgramostim Reduces Surfactant Background Burden and Number of Whole Lung Lavage Procedures in Patients with Autoimmune Pulmonary Alveolar Proteinosis (PAP): Results from the IMPALA-2 Phase 3 Clinical Trial
• 05.18.2025 - The Effects of Molgramostim on Respiratory Health-Related Quality of Life and Patient-Reported Outcomes in Patients with Autoimmune Pulmonary Alveolar Proteinosis (PAP)
• 04.16.2025 - Encore Presentation: Inhaled Molgramostim for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) – Results from the IMPALA-2 Phase 3 Clinical Trial
• 04.10.2025 - Encore Presentation: Inhaled Molgramostim Improves Pulmonary Gas Exchange, Quality of Life, and Exercise Capacity in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Recent Filings

• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 06.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.06.2025 - 8-K Current report
• 06.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.27.2025 - 8-K Current report
• 05.27.2025 - EX-99.1 EX-99.1
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]